Objectives: To study the susceptibility to azoles, echinocandins and amphotericin B for Candida species other than C. albicans isolates obtained from invasive samples over a period of four years in the Microbiology Service, University Hospital Virgen de las Nieves, Granada (Spain). Methods: The susceptibility to antifungal agents for non-albicans Candida species isolated has been studied in invasive samples obtained between October 2005 and October 2009, generally there was a single isolated per patient. The antifungal agents investigated were fluconazole, itraconazole, voriconazole, caspofungin and amphotericin B and the method used was Sensititre Yeast One® (Trek Diagnostic Systems). The results for fluconazole and itraconazole were interpreted according to the susceptibility criteria of CLSI (M27-A2). For the other antifungals, in which there are no breakpoints, we determined the MIC90. Results: We detected 127 invasive samples (belonging to 95 patients) with isolates of Candida species other than C. albicans: 76 from blood cultures (59.8%), 30 from intra-abdominal samples (23.6%), 14 from respiratory tract samples (11%), 3 from skin / soft tissue (2.4%), 2 from cerebrospinal fluid (1.6), 1 from osteoarticular tissue (0.8%) and 1 from cardiac valves (0.8%). From these samples we isolated 98 strains of yeasts and their susceptibility to antifungal agents as shown in Table 1. Conclusions: It has been verified that on these species fluconazole and itraconazole have a limited activity, except C. parapsilosis; voriconazole is the most active tested azole. Caspofungin appears to be very effective, including azole-resistant Candida species, like C. krusei. Amphotericin B is still efficient on the treatment of serious infections caused by Candida species other than C. albicans.
Full conference title:
20th European Congress of Clinical Microbiology and Infectious Diseases
- ECCMID 20th (2010)